LifeMD (LFMD) presents a compelling investment opportunity as a significantly undervalued alternative to its larger competitor, Hims & Hers Health (HIMS). The analysis suggests LFMD is nearly three times cheaper than HIMS on a key valuation metric comparing enterprise value, gross profit, and revenue growth. LFMD is also viewed as a safer play, as it avoids the major lawsuit risk over compounded weight-loss drugs that currently overhangs HIMS. The company has multiple growth catalysts, including a newly launched mental health program and an upcoming women's health service. Furthermore, management has indicated that recent issues in its core RexMD erectile dysfunction business have been resolved, signaling a return to growth.

LifeMD, Inc. (LFMD)

• The speaker refers to LFMD as "Baby HIMS" and currently finds it more compelling than HIMS due to its valuation and other factors.
• Valuation: The primary argument is that LFMD is significantly undervalued compared to HIMS.
  • Using the speaker's preferred metric, Enterprise Value / Gross Profit / Revenue Growth, LifeMD is currently "almost three times as cheap as HIMSS."
  • The speaker notes a preference for buying LFMD when it reaches this 3x cheaper level relative to HIMS.
• Growth: Expected forward revenue growth is 25% over the next 12 months, which is slower than HIMS.
• Lawsuit Risk: The speaker views LFMD as the "safer play" regarding potential lawsuits from pharmaceutical companies like Novo Nordisk.
  • This is because LFMD does not compound semaglutide (the active ingredient in popular weight-loss drugs).
  • Instead, it sells the branded medications directly from partners like Novo Nordisk and Eli Lilly.
• Business Risks: A key challenge for LFMD is that insurance often does not cover the expensive branded weight-loss drugs (mentioned at $500/month). When insurance doesn't pay, LFMD has to issue a refund.
• Identified Catalysts & Business Lines:
  • RexMD (Erectile Dysfunction): Management stated on their earnings call that the recent softness in the ED prescription business "was fixed" with marketing changes and that they expect it to return to growth.
  • LifeMD Plus: A $19/month subscription service described as the "Netflix of Doctors," which the speaker believes could gain significant traction.
  • Women's Health: The company is expected to launch a women's health program focused on menopause and osteoporosis, potentially launching this service ahead of HIMS.
  • Mental Health: Recently launched a mental health program for $99/month, a business line that has been very successful for HIMS.
  • Sleep Medication: LFMD already offers prescription medication for sleep, an area the speaker sees as a large opportunity.
  • Urgent Care: The company offers remote urgent care services, which is seen as a "huge business" and a key differentiator.
  • International Potential: The speaker sees a future opportunity for LFMD to sell virtual consultations with U.S.-licensed doctors to an international market.

Takeaways

• The sentiment for LFMD is strongly bullish, primarily driven by its attractive valuation compared to its larger competitor, HIMS.
• LFMD is presented as a lower-risk investment concerning the specific semaglutide lawsuit overhang affecting HIMS, as it does not engage in compounding the drug.
• The company has multiple growth catalysts on the horizon, including new service launches in women's health and mental health, and has reportedly already fixed issues in its core ED business.
• A potential headwind is the company's reliance on customers paying out-of-pocket for expensive branded drugs, which could be impacted by affordability issues if insurance does not provide coverage.

Hims & Hers Health, Inc. (HIMS)

• The speaker refers to HIMS as "Big HIMS" and acknowledges it as the leader in the space.
• Growth: HIMS is growing faster than LifeMD, with analysts expecting 47% revenue growth over the next 12 months.
  • However, this growth rate has recently been revised down from a previous expectation of 60% due to the end of a partnership with Novo Nordisk.
• Lawsuit Risk: A major theme is the "lawsuit overhang" from Novo Nordisk.
  • The speaker notes that "half the internet" believes a lawsuit is coming over HIMS's practice of selling compounded semaglutide.
  • This is presented as a significant risk factor that is currently weighing on the stock.
• Business Segments:
  • Weight Loss: The speaker believes the weight loss category is only a "small part of the thesis" for HIMS and that the company is diversified across many other products.
  • Erectile Dysfunction (ED): The company has acknowledged a "headwind" and "softness" in its ED business but, unlike LifeMD, has not explicitly stated that the issue has been fixed.
  • Mental Health: HIMS has a large and successful mental health business (anxiety treatment, SSRIs, etc.).

Takeaways

• The sentiment for HIMS is mixed to cautiously bearish in the short term, primarily due to its higher relative valuation and the significant lawsuit risk.
• While HIMS is the market leader with superior growth, the potential for a lawsuit from Novo Nordisk over compounded drugs is a major risk that investors should be aware of.
• The recent end of its partnership with Novo is expected to create a "dent in the quarterly revenue," leading to potentially flat or slower growth in the near term.
• The speaker suggests HIMS could benefit from expanding into areas where LifeMD is already active, such as prescription sleep medication and urgent care.